People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...

16 In the future, CRISPR diagnostics have the potential to transform the field of personalized medicine. By enabling the rapid and precise identification of genetic predispositions, these tools ...

Exchange Traded Concepts LLC trimmed its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 16.0% during the fourth quarter, according to the company in its most recent Form ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.